SEC ownership of TriSalus Life Sciences, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001826667.

Comparable stake leader

Frankenius Equity AB

Disclosed value leader

Frankenius Equity AB

Comparable rows

50/50

Latest evidence

30 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Frankenius Equity AB
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001826667
Issuer location
Westminster, CO

Ownership snapshot

Top shareholders of TriSalus Life Sciences, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Frankenius Equity AB
Disclosed value leader
Frankenius Equity AB
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G 3/4/5 13F Lead comparable stake: 14% 13D/G row: Frankenius Equity AB Showing 1-8 of 50 holder rows.

Quick read

Frankenius Equity AB leads the comparable SEC ownership view at 14%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Frankenius Equity AB's linked filing trail.
Comparable ownership Top 5
Frankenius Equity AB 14%
First Light Asset Management, LLC 11%
Mats Wahlstrom 6%
Utmost Group Plc 5.7%
James J. Pallotta 5.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Frankenius Equity AB
13D/G 3/4/5
10%+ Owner
14%
$34,179,868
6,989,748 shares
+$1,257,864 31 Jul 2025
First Light Asset Management, LLC
13F 13D/G
Company
11%
from 13D/G
$29,813,834
6,552,491 shares
30 Jun 2026
Mats Wahlstrom
13D/G 3/4/5
Director
6%
$14,610,738
2,987,881 shares
+$931,271 31 Jul 2025
Utmost Group Plc
13D/G
5.7%
$14,644,149
3,503,385 shares
+$493,867 31 Mar 2026
James J. Pallotta
13D/G
5.2%
$14,444,861
3,188,711 shares
$0 15 May 2026
Nantahala Capital Management, LLC
13D/G 13F
Company
4.1%
$9,487,139
2,040,245 shares
+$187,139 30 Sep 2025
BlackRock, Inc.
13F
Company
13F
4.3%
$12,099,442
2,659,218 shares
30 Jun 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
2.8%
$7,868,702
1,729,385 shares
30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$3,471,110.

Buys
$3,606,918
Insiders: 6
Sells
$135,808
Insiders: 5
Net
+$3,471,110
Shares: +1,128,044
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 1,162,267 Shares: 34,223
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 726,782 34,223 $1,821,429 $135,808 +$1,685,621
6-9 435,485 0 $1,785,488 $0 +$1,785,488
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 25 reporting-owner rows connected to TriSalus Life Sciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
25
Largest Forms 3/4/5 holder
MedTech Acquisition Sponsor LLC
Net 12M change
+$3,471,112
Latest report
01 Jul 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
MedTech Acquisition Sponsor LLC 10%+ Owner $65,538,115 Mixed 26 Jun 2023
Frankenius Equity AB 10%+ Owner $27,190,119 Mixed 31 Jul 2025
Mats Wahlstrom Director $11,631,214 +$151,800 +1.3% Mixed 15 May 2026
Kerry R. Hicks Director $9,269,600 Mixed 14 May 2026
David J. Matlin Director $5,292,840 Mixed 14 May 2026
Michael P. Stansky Director $4,919,811 +$3,005,502 +157% Filing P/S 15 May 2026
Szela Mary T. CEO and President, Director $4,310,732 +$148,390 +3.6% Mixed 30 Jun 2026
Sean Murphy Director $3,818,390 Mixed 12 Jun 2025
George Kelly Martin Director $1,359,468 Filing P/S 28 Aug 2024
David Patience Chief Financial Officer $1,044,428 +$32,247 +3.2% Mixed 01 Jul 2026
Arjun Jj Desai Director $911,899 Filing P/S 12 Jun 2025
Bryan F. Cox Chief of Research $673,269 -$13,085 -1.9% Filing P/S 11 Mar 2026
James Alecxih President, Device Technology $521,147 Mixed 10 Aug 2023
Richard Marshak Chief Commercial Officer $513,276 -$15,659 -3% Mixed 30 Jun 2026
Jennifer Stevens Chief Regulatory Officer $511,333 -$14,509 -2.8% Filing P/S 11 Mar 2026
James Emmett Young Chief Financial Officer $428,854 Mixed 19 May 2025
Jodi Devlin Chief of Clinical Operations $401,139 -$13,171 -3.2% Filing P/S 11 Mar 2026
Steven C. Katz Chief Medical Officer $377,229 Mixed 12 Feb 2024
Richard Henry Marshall Chief Medical Officer $360,000 Mixed 29 Jun 2026
William Valle Director $332,964 +$124,997 +60% Mixed 14 May 2026

Recent insider transactions for TriSalus Life Sciences, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
David Patience TLSI Common Stock Tax liability -5.31% -14,650 261,107 01 Jul 2026 Direct
Szela Mary T. TLSI Common Stock Award 0.37% 3,990 1,077,683 30 Jun 2026 Direct
Richard Marshak TLSI Common Stock Award 0.44% 561 128,319 30 Jun 2026 Direct
Richard Henry Marshall TLSI Common Stock Award 200% 60,000 90,000 29 Jun 2026 Direct
Richard Henry Marshall TLSI Employee Stock Option (right to buy) Award 90.2% 120,000 253,000 29 Jun 2026 Direct
Richard Marshak TLSI Common Stock Sale -0.43% $1,450 $2.67 -543 125,101 15 May 2026 Direct
Mats Wahlstrom TLSI Common Stock Purchase 68.5% $151,800 $2.53 60,000 147,555 15 May 2026 Direct
Michael P. Stansky TLSI Common Stock Purchase 100.2% $500,000 $2.50 200,000 399,698 15 May 2026 By Skyview Investments LLC
Michael P. Stansky TLSI Common Stock Purchase 49.4% $1,025,000 $2.50 410,000 1,240,722 15 May 2026 Direct
Szela Mary T. TLSI Common Stock Purchase 3.87% $102,776 $2.59 39,682 1,065,215 15 May 2026 Direct
David Patience TLSI Common Stock Purchase 2.64% $17,253 $2.43 7,100 275,757 15 May 2026 Direct
Gary B. Gordon TLSI Common Stock Purchase 16% $24,600 $2.46 10,000 72,510 15 May 2026 Direct
Kerry R. Hicks TLSI Common Stock Award 5.48% 28,201 542,790 14 May 2026 Direct
Kerry R. Hicks TLSI Director Stock Option (right to buy) Award 63.2% 56,403 145,625 14 May 2026 Direct
Mats Wahlstrom TLSI Common Stock Award 456.7% 71,828 87,555 14 May 2026 Direct
Mats Wahlstrom TLSI Director Stock Option (right to buy) Award 37.4% 75,204 276,149 14 May 2026 Direct
Gary B. Gordon TLSI Common Stock Award 540.7% 52,754 62,510 14 May 2026 Direct
Gary B. Gordon TLSI Director Stock Option (right to buy) Award 100.3% 56,403 112,653 14 May 2026 Direct
David J. Matlin TLSI Common Stock Award 4.03% 51,266 1,323,210 14 May 2026 Direct
David J. Matlin TLSI Director Stock Option (right to buy) Award 86.8% 56,403 121,403 14 May 2026 Direct
William Valle TLSI Common Stock Award 173% 52,754 83,241 14 May 2026 Direct
William Valle TLSI Director Stock Option (right to buy) Award 100.3% 56,403 112,653 14 May 2026 Direct
Michael P. Stansky TLSI Common Stock Award 5.54% 43,590 830,722 14 May 2026 Direct
Michael P. Stansky TLSI Director Stock Option (right to buy) Award 50.8% 47,003 139,540 14 May 2026 Direct
Szela Mary T. TLSI Common Stock Sale -2.07% $61,384 $3.85 -15,944 752,987 17 Mar 2026 Direct
Jodi Devlin TLSI Common Stock Sale -0.28% $1,125 $4.12 -273 97,364 16 Mar 2026 Direct
Bryan F. Cox TLSI Common Stock Sale -0.35% $2,385 $4.12 -579 163,415 16 Mar 2026 Direct
Richard Marshak TLSI Common Stock Sale -0.38% $1,726 $4.12 -419 110,397 16 Mar 2026 Direct
Jennifer Stevens TLSI Common Stock Sale -0.62% $3,189 $4.12 -774 124,110 16 Mar 2026 Direct
Jodi Devlin TLSI Common Stock Sale -1.78% $7,247 $4.09 -1,772 97,637 12 Mar 2026 Direct
Bryan F. Cox TLSI Common Stock Sale -0.89% $6,000 $4.09 -1,467 163,994 12 Mar 2026 Direct
Richard Marshak TLSI Common Stock Sale -1.41% $6,499 $4.09 -1,589 110,816 12 Mar 2026 Direct
Jennifer Stevens TLSI Common Stock Sale -1.23% $6,348 $4.09 -1,552 124,884 12 Mar 2026 Direct
Jodi Devlin TLSI Common Stock Sale -1.16% $4,799 $4.13 -1,162 99,409 11 Mar 2026 Direct
Bryan F. Cox TLSI Common Stock Sale -0.68% $4,700 $4.13 -1,138 165,461 11 Mar 2026 Direct
Richard Marshak TLSI Common Stock Sale -1.27% $5,984 $4.13 -1,449 112,405 11 Mar 2026 Direct
Jennifer Stevens TLSI Common Stock Sale -0.94% $4,973 $4.13 -1,204 126,436 11 Mar 2026 Direct
Szela Mary T. TLSI Common Stock Sale -0.56% $17,999 $4.13 -4,358 768,931 11 Mar 2026 Direct
David Patience TLSI Common Stock Purchase 1.38% $14,994 $4.10 3,657 268,657 23 Feb 2026 Direct
Gary B. Gordon TLSI Common Stock Purchase $40,000 $4.10 9,756 9,756 23 Feb 2026 Direct
William Valle TLSI Common Stock Purchase $124,997 $4.10 30,487 30,487 23 Feb 2026 Direct
Szela Mary T. TLSI Common Stock Purchase 4.1% $124,997 $4.10 30,487 773,289 23 Feb 2026 Direct
Michael P. Stansky TLSI Common Stock Purchase 142.1% $480,512 $4.10 117,198 199,698 23 Feb 2026 By LLC
Michael P. Stansky TLSI Common Stock Purchase 44.9% $999,990 $4.10 243,900 787,132 23 Feb 2026 Direct
Michael P. Stansky TLSI Director Stock Option (right to buy) Award 92,537 92,537 04 Feb 2026 Direct
Szela Mary T. TLSI Common Stock Award 0.21% 2,100 1,023,826 31 Dec 2025 Direct
Richard Marshak TLSI Common Stock Award 0.34% 449 131,758 31 Dec 2025 Direct
Bryan F. Cox TLSI Common Stock Award 31.6% 40,000 166,599 24 Nov 2025 Direct
Bryan F. Cox TLSI Employee Stock Option (right to buy) Award 44% 80,000 261,954 24 Nov 2025 Direct
Jodi Devlin TLSI Common Stock Award 98.9% 50,000 100,571 24 Nov 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .